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LAWS AND ETHICS AFFECTING
CLINICAL TRIALS IN AFRICA
MARK BARNES & NICK WALLACE
I. INTRODUCTION
In recent decades, clinical trials involving human subjects have become increasingly globalized as scientists and medical professionals conduct research in
developing countries.1 Some of this research seeks to study specific diseases that
are rare in the United States, such as malaria, dengue fever and tuberculosis. 2
These studies can help address the lack of treatment options “available for the
diseases that have the greatest impact in the developing world.”3 Other research
may be motivated by the opportunity to secure U.S. Food and Drug Administration (“FDA”) approval of a pharmaceutical product, biological product, or medical device.4
For industry sponsors, conducting clinical trials abroad offers, in some
cases, the possibility of significant savings through shorter trial time frames and
lower costs per participant. Trials abroad can be completed more rapidly because
recruiting human subjects in foreign countries has proven substantially easier
than recruiting volunteers domestically.5 The duration of a clinical trial holds
© 2018 Mark Barnes & Nick Wallace.
1. Seth W. Glickman et al., Ethical and Scientific Implications of the Globalization of Clinical Research, 360 NEW ENG. J. MED. 816, 816 (2009) (“Pharmaceutical and device companies have embraced
globalization as a core component of their business models, especially in the realm of clinical trials.”);
see, e.g. DANIEL R. LEVINSON, U.S. DEP’T OF HEALTH AND HUMAN SERVICES, OFFICE OF INSPECTOR
GENERAL, CHALLENGES TO FDA’S ABILITY TO MONITOR AND INSPECT FOREIGN CLINICAL TRIALS i–ii
(2010) (observing that many clinical trials for FDA-regulated drug products are performed outside the
United States).
2. See REMIGIUS N. NWABUEZE, LEGAL AND ETHICAL REGULATION OF BIOMEDICAL RESEARCH IN
DEVELOPING COUNTRIES 2–3 (2013); see, e.g., DNDI’S POLICIES, DRUGS FOR NEGLECTED DISEASES
INITIATIVE, http://www.dndi.org/about-dndi/dndi-policies (last visited Sept. 17, 2016) (stating its mission
to facilitate ways to promote more research and development for neglected diseases); Finnuala Kelleher,
The Pharmaceutical Industry’s Responsibility for Protecting Human Subjects of Clinical Trials in Developing Nations, 38 COLUM. J. L. & SOC. PROBS. 67 (2004) (stating that trial sponsors are attracted to developing countries for the prevalence of diseases that are rare in the United States).
3. What We Do: Discovery & Translational Sciences Strategy Overview, BILL & MELINDA GATES
FOUNDATION,
http://www.gatesfoundation.org/What-We-Do/Global-Health/Discovery-and-Translational-Sciences (last visited Sept. 17, 2017) (recognizing the need to “advance the goal of creating solutions that can be deployed, accepted, and sustained in the developing world” to help support preventative
and curative therapies for diseases that are significantly left untreated in developing countries).
4. See Glickman et al., supra note 1 (stating that pharmaceutical companies seek to conduct clinical
trials in developing countries because trials there are more cost-effective and the trials needed for FDA
new drug approval can be completed more rapidly); see also NWABUEZE, supra note 2, at 4 (noting that
pharmaceutical companies can bring their new drugs to market “cheaper and faster” by conducting their
research in developing countries).
5. See Yevgenia Shtilman, Pharmaceutical Drug Testing in the Former Soviet Union: Contract
Research Organizations as Broker-Dealers in an Emerging Testing Ground for America’s Big Pharma,
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serious financial implications for study sponsors. In 2000, one estimate projected
that a one-day delay in bringing a major drug to market could result in a loss of
$1.3 million in unrealized sales for a pharmaceutical company.6 In some cases,
the overall costs of conducting clinical research abroad are significantly lower
than the costs of conducting the same research domestically. Some reports from
pharmaceutical sponsors suggest that a second-tier center in the United States is
expected to charge more than ten times what a first-rate academic medical center
in India charges per case report.7
Today, significant clinical research supporting FDA applications is conducted abroad. In 2008, 80 percent of marketing applications approved by the
FDA for drugs or biologics relied on some data from foreign clinical trials.8 A
2007 study analyzed the industry-sponsored Phase III trials listed in the ClinicalTrials.gov registry and found that, for the 20 largest pharmaceutical companies, approximately one third of the trials were conducted outside of the United
States and a majority of the study sites were located outside the United States
(“ex-U.S.” sites).9 As of September 14, 2017, ClinicalTrials.gov showed 47 percent of registered studies as having a “non-U.S. only” location.10 Consequently,
the legal and ethical implications of clinical trials conducted abroad affect a significant number of research participants. Between October 2007 and September
2008, trials conducted at 6,500 foreign research sites involved more than 200,000
subjects.11
The ethical and legal challenges affecting clinical trials conducted in Africa
are particularly pronounced, even though African countries host fewer clinical
trial sites reported to the FDA than many other regions.12 In many developing
countries, laws, or the lack of enforcement of laws, may offer reduced protections
29 B.C. THIRD WORLD L.J. 425, 432–34 (2009) (describing domestic barriers, such as the lack of volunteers and stringent federal regulations, that delay the progression of clinical trials in the United States,
motivating pharmaceutical companies to seek independent contractors who can help facilitate faster clinical trials in foreign countries with lighter regulatory frameworks).
6. See id. at 433.
7. See Glickman, supra note 1; see also Shtilman, supra note 5, at 441 (explaining how overseas
clinical trials gain popularity by costing significantly less than trials in the United States).
8. See LEVINSON, supra note 1, at ii.
9. See Glickman, supra note 1; see also Shtilman, supra note 5, at 426, 431–32 (noting that both
the need for large numbers of participants as well as insufficient American volunteers influence the pharmaceutical companies’ decision to conduct trials abroad).
10. See TRENDS, CHARTS, AND MAPS, https://clinicaltrials.gov/ct2/resources/trends (last visited Sept.
17, 2017).
11. LEVINSON, supra note 1, at 11; United States Senate, References, http://www.senate.gov/reference/glossary_term/fiscal_year.htm (last visited Sept. 17, 2017) (identifying the federal fiscal year as a
period beginning October 1 and ending September 30).
12. See LEVINSON, supra note 1, at 12 (noting that the Office of the Inspector General (“OIG”) analyzed FDA marketing applications approved in 2008 and found that less than 10 percent of the foreign
clinical trial subjects and foreign sites were located in the Africa and the Middle East region. The number
of clinical trials conducted in Africa and not reported to the FDA is unknown).
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to human subjects, and local regulatory bodies may lack the capacity to monitor
clinical trials adequately.13 Clinical trials involving human subjects raise a
unique set of ethical complications when carried out in developing countries.
This article lays out the sources of law and ethical principles that apply when
U.S. academic institutions and corporations sponsor or conduct clinical trials in
African countries. Section II of this Article outlines laws that govern research
conducted in Africa. In particular, Section II focuses on U.S. statutes and regulations that apply extraterritorially to research conducted abroad and notes certain gaps in the legal protections afforded to human subjects at ex-U.S. sites.
Section III of this Article focuses on the specific application of ethical research
principles to clinical research conducted in Africa, including to research conducted outside the parameters of legal protections for human subjects. This Section briefly outlines the evolution of ethical guidelines governing human subjects
research and applies principles of ethical conduct to certain paradigms likely to
emerge when foreign institutions and multi-national companies conduct clinical
trials in Africa.
II. LAWS APPLICABLE TO CLINICAL TRIALS CONDUCTED IN AFRICA
Both foreign and U.S. law may apply when clinical trials are conducted at
ex-U.S. sites by U.S.-based or U.S.-affiliated entities or researchers. The nonU.S. country where the trial site is found may have laws applicable to a range of
relevant research and non-research activities. Additionally, certain U.S. statutes
and regulations apply extraterritorially and regulate conduct at an ex-U.S. clinical research site if the research is funded by the U.S. government or if the data
from the site are to be submitted to support a U.S. regulatory filing.14 Other U.S.
laws apply to all activity, regardless of whether U.S. funding or regulatory approval is involved.15 Not infrequently, U.S. laws regulate a number of aspects
of ex-U.S. clinical trials, including the site’s protection of human subjects, the
export of certain materials and data, payments made to officials of foreign governments (including medical staff and officials of government-affiliated hospitals), and registration of the ex-U.S. clinical trial. In addition to identifying certain research-related activities that are subject to U.S. or other national
regulation, this Section identifies a category of certain ex-U.S. clinical trials for
which no country’s human subjects protection law may apply and specifies the

13. See Glickman, supra note 1, at 818 (noting further that regulatory bodies have limited information
regarding clinical trials conducted in foreign countries and therefore are unable to serve as effective monitors of the quality of such research).
14. See, e.g., 21 C.F.R. § 312.120 (2008).
15. See, e.g., William Dubois, Note, New Drug Research, the Extraterritorial Application of the FDA
Regulations, and the Need for International Cooperation, 36 VAND. J. TRANSNAT’L L. 161, 189–90
(2003).
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circumstances in which certain sponsors and investigators have a heightened ethical duty to self-regulate to ensure that their research is conducted in conformity
with the applicable ethical requirements.
A. Laws of the Country in Which the Clinical Trial Site is Located
Before beginning a program of ex-U.S. clinical trials, research sponsors and
investigators must be aware of the legal requirements that pertain to their activities in the jurisdictions in which they conduct or sponsor clinical trials. Some
countries in Africa have laws that govern the conduct of clinical trials specifically, and most have non-research-specific laws affecting the operations of clinical trials.16 For example, a host country may have laws regulating the drugs,
devices or biotechnology used in the clinical trial; national and local taxation
laws; labor and wage laws; immigration laws regulating work permits and business visas for the site’s expatriate staff; professional licensure laws governing
the site’s doctors, nurses and pharmacists; privacy laws and data export laws;
tissue and blood sample export control laws; and intellectual property laws.
As one example, South Africa has adopted detailed legal requirements for
the protection of human research subjects and data privacy.17 These requirements are not identical to the U.S. human subjects and data privacy protections
that apply extraterritorially.18 Clinical trials involving human research in South
Africa must, among other requirements, register the research in the South African National Clinical Trials Register, submit the research proposal for ethics review and approval to a health research ethics committee registered in South Africa, and provide detailed information in order to obtain legally adequate
informed consent.19
South African law protects the privacy of “personal information,” which is
broadly defined to include biometric information, medical history, demographic
information, and contact information.20 Because the law requires the “responsible party” to “take reasonably practicable steps to ensure that the data subject is
aware of . . . the fact that . . . the responsible party intends to transfer the information to a third country,” many sponsors of clinical trials in South Africa must
notify the subject of their intent to transfer the data to one or more foreign countries for further analysis.21 Additionally, if the sponsor intends to submit the data

16. See, e.g., NATIONAL AGENCY FOR FOOD AND DRUG ADMINISTRATION AND CONTROL, NAFDAC
GOOD CLINICAL PRACTICE GUIDELINES 2016, http://www.nafdac.gov.ng/index.php/guidelines/cliinicaltrials.
17. See generally Protection of Personal Information Act 4 of 2013 (S. Afr.) (protecting “personal
information processed by public and private bodies,” including information of human test subjects).
18. See infra Part II.B.
19. See Government Notice (GN) R719/2014 (S. Afr.).
20. Protection of Personal Information Act 4 of 2013 §1 (S. Afr.).
21. Id. at § 18(1)(g).
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to multiple foreign regulatory agencies to gain approval for marketing a drug,
device or biologic product, the sponsor will likely wish to de-identify the personal information contained in the data to avoid the requirement to describe to
the research subject “the level of protection afforded to the information by” the
third countries to which the personal information is transferred.22
Other countries in Africa may, however, lack robust legal regimes to protect
human research subjects.23 The Office for Human Research Protections
(“OHRP”) of the U.S. Department of Health and Human Services (“DHHS”)
maintains an International Compilation of Human Research Standards (“the
Compilation”).24 The Compilation catalogues more than 1,000 laws, regulations,
and guidelines governing human subjects research in 126 countries.25 As of the
2017 edition of the Compilation, OHRP identified only 25 African countries with
laws specifically governing general human subjects research; research injury;
clinical trial registries; drugs and devices; human biological materials; genetic
research; or embryos, stem cells, and cloning.26 Some scholars have noted that
this absence of regulation may stem from an effort to attract the benefits of clinical research to countries where there is little access to medical research to benefit
the population.27
When conducting clinical trials in countries that lack laws specifically governing human subjects research, research sponsors and investigators may find
themselves operating entirely outside the familiar legal frameworks in the U.S.
that protect research subjects. U.S. laws protecting human subjects do not reach
some purely private research conducted in other countries, as discussed below in
Section II.B. When clinical trial sponsors and investigators operate outside clear
legal regimes protecting human subjects, they have an ethical and moral duty to
ensure that their conduct meets the requirements laid out in the guidelines for
human subjects research, as discussed in Part III.

22. Id.
23. See Benjamin M. Meier, International Protection of Persons Undergoing Medical Experimentation: Protecting the Right of Informed Consent, 20 BERKELEY J. INT’L L. 513, 532–33 (2002).
24. See OFF. FOR HUM. RES. PROTECTIONS, U.S. DEP’T OF HEALTH & HUM. SERV., INT’L
COMPILATION OF HUM. RES. STANDARDS (2017).
25. See id.
26. See id. at 2, 157–66 (noting that the twenty-five identified countries with relevant laws are: Benin, Botswana, Burkina Faso, Cameroon, Côte-d’Ivoire, Democratic Republic of Congo, Ethiopia, Gambia, Ghana, Guinea, Kenya, Liberia, Malawi, Mozambique, Nigeria, Rwanda, Senegal, Sierra Leone,
South Africa, Sudan, Tanzania, Tunisia, Uganda, Zambia, and Zimbabwe. Additionally, OHRP notes that
it has consulted “in-country persons” to review the listings for accuracy and completeness, but the ongoing
issuance of new standards prevents the Compilation from serving as an “exhaustive source of all current
applicable laws.”).
27. See Meier, supra note 23.
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B. United States Laws That Apply Extraterritorially
Some U.S. laws that protect human research subjects apply extraterritorially when the federal government funds or takes regulatory action based on data
from a foreign clinical trial.28 Other U.S. laws that do not involve the protection
of human research subjects apply extraterritorially to clinical trials conducted
outside the U.S. and regulate aspects of those trials, including the transfer of materials and data, payments to foreign officials, and registration of the trials. This
Subsection analyzes the requirements of these laws as well as their applicability
to various types of clinical trials.
1. The Common Rule
The Federal Policy for the Protection of Human Subjects, located at 45
C.F.R. part 46, applies extraterritorially, governing all research on human subjects that is “conducted, supported, or otherwise subject to regulation by the federal government outside the United States.”29 The regulations at 45 C.F.R. part
46 contain four subparts.30 Subpart A, known as the Common Rule, provides
basic rules governing research involving human subjects. Additional subparts
impose further requirements on human subjects research involving pregnant
women,31 prisoners,32 and children as subjects.33
Human subjects research that is covered by the Common Rule must be approved by an institutional review board (“IRB”), which has the authority to require modifications to be made or to disapprove covered research activities.34
The Common Rule further requires that all covered research must secure “the
legally effective informed consent of the subject or the subject’s legally authorized representative.”35 Clinical trials in Africa that are covered by the Common
Rule may face particular challenges in gaining adequate informed consent of research subjects, as discussed below in Subsection III.B.i.

28. See Jennifer S. Bard, Closing the Gaps in Human Subject Research Law: Regulating Clinical
Research Conducted Outside of the United States, 21 ANNALS OF HEALTH L. (ASLME SPEC. ED.) 201,
202–3 (2012).
29. 45 C.F.R. § 46.101(a) (2015) (Specifically, the Common Rule applies to the agencies and departments that that have taken “appropriate administrative action to make the policy applicable to such research.” Currently, the Common Rule has been “codified in separate regulations by 15 Federal departments and agencies,” with an additional three departments or agencies complying with the Common Rule,
though they have not issued the Common Rule in regulations); see e.g., U.S. DEP’T OF HEALTH & HUM.
SERV., FED. POL’Y FOR THE PROTECTION OF HUM. SUBJECTS (‘COMMON RULE,’)
http://www.hhs.gov/ohrp/humansubjects/commonrule/.
30. See 45 C.F.R. § 46 (2009).
31. See 45 C.F.R. §§ 46.201–07 (2009).
32. See 45 C.F.R. §§ 46.301–06 (1978).
33. See 45 C.F.R. §§ 46.401–09 (1997).
34. See 45 C.F.R. § 46.109 (2005).
35. 45 C.F.R. § 46.116 (2005).
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Clinical trials in Africa are governed by the Common Rule’s human subjects protections if the research falls under any of the three regulated categories.36
Clinical trials that receive National Institutes of Health (“NIH”) or Centers for
Disease Control and Prevention (“CDC”) funding, for example, are “supported”
by a federal agency that follows the Common Rule and are subject to its human
subjects protections.37 Because the NIH and CDC play a significant role in funding new drug, vaccine and public health research, it is not uncommon for research
carried out abroad to be subject to the Common Rule’s requirements.
Clinical trial sponsors or investigators may apply for a discretionary waiver
of the Common Rule’s extraterritorial applicability.38 When covered research
takes place in a foreign country where human subjects protections differ from
the Common Rule, a U.S. department or agency head may approve the substitution of the foreign procedures in lieu of the Common Rule’s requirements.39
However, the official may only approve such a substitution if the official determines that the policies afford protections that are at least equivalent to those provided in the Common Rule.40 Because some countries in Africa lack legal protections for human research subjects, this discretionary waiver will only be
available when clinical trials are conducted in the subset of countries with protections for human subjects, and then only if the country’s protections are determined to be at least equivalent to those provided under the Common Rule.
2. Food & Drug Administration Regulations Governing Human Subjects
Protections in Trials Seeking Marketing Approval of a Drug, Device or
Biological Product
When clinical trials are conducted in Africa in order to generate data supporting a New Drug Application (“NDA”), a Premarket Approval Application
(“PMA”) for a medical device, or a Biologics License Application (“BLA”), the
clinical trials must meet requirements imposed by the FDA.41 The FDA must
approve an application for any new drug, medical device or biologic delivered
36. See supra note 1.
37. See NAT’L INST. OF HEALTH, CLINICAL R. POL’Y, http://osp.od.nih.gov/office-clinical-researchand-bioethics-policy/clinical-research-policy/research-involving-human-subjects (last visited Sept. 18,
2017) (noting that the National Institutes of Health, as an agency of the United States Department of
Health and Human Services follows the Common Rule); see also U.S. DEP’T OF HEALTH AND HUMAN
SERV., “HUMAN RESEARCH PROTECTIONS” POL’Y (2010), http://www.cdc.gov/od/science/integrity/docs/cdc-policy-human-research-protections.pdf (last visited Sept. 18, 2017) (noting that the Common Rule is applicable to all research activities of the Centers for Disease Control and Prevention).
38. See IRB Common Rule and HIPAA Waiver Approval, RESEARCH DATA ASSISTANCE CENTER,
http://www.resdac.org/cms-data/request/materials/irb-common-rule-and-hipaa-waiver-approval (last visited Sept. 18, 2017) (identifying the criteria and procedures for obtaining a waiver).
39. See 45 C.F.R. § 46.101(h) (2015).
40. See id.
41. See 21 C.F.R. § 314.2 (2015) (drugs); 21 C.F.R. § 814.1 (2015) (medical devices); 21 C.F.R. §
601.2 (2012) (biologics).
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into interstate commerce in the United States.42 FDA requirements for foreign
studies conducted to support a PMA are codified separately from the requirement
for foreign studies conducted to support an NDA or BLA.43 Substantively, however, the requirements are similar for the three applications.
The FDA allows applicants to submit as support for an NDA or BLA “a
well-designed and well-conducted foreign clinical study not conducted under an
Investigational New Drug Application (“IND”), if the following conditions are
met: “The study was conducted in accordance with good clinical practice
(“GCP”) . . . and; FDA is able to validate the data from the study through an
onsite inspection if the agency deems it necessary.”44
Under FDA regulations, GCP includes review and approval (or provision
of a favorable opinion) by an independent ethics committee (“IEC”) and “obtaining and documenting the freely given informed consent of the subject.”45 The
FDA will only accept a foreign clinical study of a medical device not conducted
under an Investigational Device Exemption (“IDE”) as support for a PMA if “the
data are valid” and the research has been conducted “in conformance with the
‘Declaration of Helsinki’ or the laws and regulations of the country in which the
research is conducted, whichever accords greater protection to human subjects.”46
Foreign clinical trials generating data to support an NDA or BLA are subject to requirements to obtain approval by a review board and to obtain a subject’s informed consent under the FDA regulations.47 Likewise, the Declaration
of Helsinki, which contains the minimum requirements that a study must meet to
be considered as support for a PMA, requires the submission of the research protocol to a “research ethics committee.”48 Additionally, the Declaration requires

42. See id.
43. See supra note 1.
44. 21 C.F.R. § 312.120(a)(i)–(ii) (2015). Under this section, GCP is defined as a “standard for the
design, conduct, performance, monitoring, auditing, recording, analysis, and reporting of clinical trials in
a way that provides assurance that the data and reported results are credible and accurate and that the
rights, safety, and well-being of trial subjects are protected.” It includes review by an independent board
and obtaining subjects’ informed consent; see also 21 C.F.R. § 312.120(b) (2015) (describing supporting
information that the FDA requires of an NDA applicant submitting data from a foreign clinical study not
conducted under an IND).
45. 21 C.F.R. § 312.120(a)(i) (2015); see also 21 C.F.R. § 50.20 (2015) (applying the informed consent requirement to foreign clinical trials involving human subjects used to generate data for FDA applications).
46. 21 C.F.R. § 814.15(b) (2015).
47. See supra note 1.
48. See World Medical Association, Inc., WMA Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects, 59 WORLD MED. J. 199, 200 (2013)(The Declaration explains
that a “research protocol must be submitted for consideration, comment, guidance, and approval to the
concerned research ethics committee before the study”; such a committee must be “independent,” “transparent,” “qualified,” and free from any “undue influence” on behalf of the researcher).
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that investigators obtain the informed consent of human subjects.49 The particular challenges involved in obtaining informed consent of subjects in clinical trials
conducted in Africa are discussed below in Subsection III.B.i.
4. Privacy and Confidentiality Regulations
The Health Insurance Portability and Accountability Act of 1996 and the
regulations adopted thereunder (collectively, “HIPAA”) impose confidentiality
requirements on protected health information (“PHI”) held by a “covered entity.”50 Covered entities include (1) a health plan, (2) a health care clearinghouse,
and (3) a health care provider, if that entity or person transmits any health information in electronic form in connection with a transaction covered by the subchapter.51 PHI is defined as “individually identifiable health information” that is
transmitted by or maintained in electronic media or in any other form or medium.52
Avoiding potential extraterritorial application of HIPAA has influenced the
administration of international clinical trials. Some sponsors have faced concern
that HIPAA might apply to the conduct of HIPAA-covered entities when they
gather PHI abroad.53 The HHS Secretary’s Advisory Committee on Human Research Protections (“SACHRP”) notes that some clinical research sponsors have
“determined that these concerns can be eased by no longer relying on Covered
Entities (such as academic research institutions or universities) to assist in the
coordination of multi-national clinical trials.”54 To reverse any regulatory bias
against covered entities that could play a valuable role as investigators on foreign
clinical trials, SACHRP recommends that “the Department give clear guidance
in the near future on the scope of HIPAA’s application in the international context” and that the guidance restrict the extraterritorial application of HIPAA insofar as possible.55 However, because the Department has not yet issued this
guidance, commercial sponsors of clinical trials in Africa can, and often do,
choose to directly contract with local, ex-U.S. hospitals and clinics to conduct
trials, bypassing covered entity medical centers in the U.S. that, before HIPAA,
might have acted as the data coordinating center or as the lead clinical trial site.
Sponsors also often choose to rely on Contract Research Organizations or other

49. See id. at 200–01.
50. See 45 C.F.R. § 164.508(a) (2015).
51. See 45 C.F.R. § 160.102(a) (2015).
52. 45 C.F.R. § 160.103 (2015).
53. See Secretary’s Advisory Committee on Human Research Protections: Appendix H, U.S. DEP’T
OF HEALTH & HUM. SERV. OFF. FOR HUM. RES. PROTECTIONS, http://archive.hhs.gov/ohrp/sachrp/appendixh.html (last updated Feb. 9, 2005).
54. Id.
55. Id.
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entities that are not HIPAA covered entities when initiating clinical trials in Africa.
It should be noted that HIPAA is not the only source of a confidentiality
requirement that applies extraterritorially. Even when HIPAA does not apply to
foreign clinical trials, the Common Rule requires that an IRB consider whether
the research plan includes adequate provisions to protect the privacy of subjects
and to maintain the confidentiality of the data.56 Therefore, a clinical trial conducted at one or more sites in Africa that is not subject to HIPAA may still be
subject to privacy and confidentiality requirements imposed through an IRB, if
the clinical research is subject to FDA human subjects regulations.57 As discussed above in Subsection II.B.ii, pharmaceutical clinical trials that generate
research used to support a drug application to the FDA are subject to FDA regulations protecting human subjects, and therefore are already likely to face the
imposition of confidentiality requirements on clinical trials conducted in Africa.
5. Export & Import Control Regulations
When U.S. entities conduct clinical trials in Africa, certain export control
regulations may restrict their ability to convey some materials and technology
outside the United States. The International Traffic in Arms Regulations
(“ITAR”)58 and Export Administration Regulations (“EAR”)59 apply to all exports in clinical trials, regardless of whether the federal government has a role in
funding or receiving data from the trials.
ITAR’s United States Munitions List designates the “articles, services, and
related technical data” that are subject to controls as defense articles and services
under the Arms Export Control Act.60 The Munitions List designates numerous
toxicological agents, including chemical agents, biological agents, and associated equipment, as defense articles.61 In order to export any of these agents and
associated equipment for use in clinical trials, the sponsor must obtain the requisite licenses under ITAR.62

56. See 45 U.S.C. § 46.111(a)(7) (2016).
57. See 45 C.F.R. § 46.101 (2016) (applying the privacy and confidentiality requirements of 45
C.F.R. § 46.111(a)(7) “to all research involving human subjects conducted, supported or otherwise subject
to regulation by any federal department or agency which takes appropriate administrative action to make
the policy applicable to such research,” which includes the FDA).
58. See 22 C.F.R. § 120 et seq. (2015).
59. See 15 C.F.R. § 730 et seq. (2016).
60. See 22 C.F.R. § 121.1(a) (2015).
61. See 22 C.F.R. § 121.1 (2016) (Category XIV—Toxicological Agents, Including Chemical
Agents, Biological Agents, and Associated Equipment); see also 22 C.F.R. § 120 et seq. (2016).
62. See 22 C.F.R. § 123.1 (2016) (requiring that “any person who intends to export or import temporarily a defense article must obtain the approval of the Directorate of Defense Trade Controls prior to the
export or temporary import, unless the export or temporary import qualifies for an exemption under the
provisions of this subchapter.”).
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No African countries appear on the current list of countries to which the
United States categorically refuses to grant a license for the export of defense
articles and services.63 However, the United States generally also will refuse to
issue an export license under ITAR for exports to certain nations, such as when
a United Nations embargo applies to a nation and a potential export is also contained on the Munitions List.64 As of September 2017, countries in Africa subject to a policy of denials for the export of defense articles and services, except
when a license may be issued on a case-by-case basis, include the Central African
Republic, the Democratic Republic of Congo, Eritrea, Libya, Somalia, Sudan,
and Zimbabwe.65
The EAR regulates “‘dual-use’ item[s] . . . [having] civil applications as
well as terrorism and military or weapons of mass destruction (WMD)-related
applications.”66 Relevant facts for determining the applicability of the EAR export prohibitions include the listing of an item on the Commerce Control List,
the identity of a destination country, and the end-use.67 Because the Commerce
Control List contains various biological and chemical agents that have dual uses,
those conducting clinical trials in Africa must ensure that exports of materials for
use in their clinical trials are not prohibited under the EAR.
6. Foreign Corrupt Practices Act
Entities that operate in the U.S. must comply with the Foreign Corrupt Practices Act of 1977 (“FCPA”) when sponsoring or conducting clinical trials outside
of the U.S.68 The FCPA makes it unlawful for any person to offer, promise or
pay “any money. . . [or] anything of value” to certain foreign persons in order to
influence official acts or obtain business.69
FCPA risks are especially relevant to sponsors and investigators of ex-U.S.
clinical trials, as the former Assistant Attorney General for the Criminal Division
of Department of Justice has noted a “significant risk” of FCPA violations in the

63. See 22 C.F.R. § 126.1(a), (c)(2)–(3) (1993).
64. See 22 C.F.R. § 126.1(c) (1993).
65. See 22 C.F.R. § 126.1(d)(2) (1993).
66. 15 C.F.R. § 730.3 (2013).
67. See 15 C.F.R. § 736.2(a) (1996).
68. See generally 15 U.S.C. § 78dd-1 (2010).
69. 15 U.S.C. § 78dd-1(a)(1)–(3) (2010) (individuals to whom such offers, promises or payments
may not be made include: 1) “any foreign official for purposes of influencing any act or decision of such
foreign official in his official capacity,” 2) “any foreign political party or official thereof or any candidate
for foreign political office for purposes of—influencing any act or decision of such party, official, or
candidate in its or his official capacity” in order to assist in “obtaining or retaining business for or with,
or directing business to, any person,” and 3) any intermediary with the knowledge that “all or a portion of
such money or thing of value will be offered, given, or promised, directly or indirectly, to any foreign
official, to any foreign political party or official thereof, or to any candidate for foreign political office”
for the prohibited purposes).
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field.70 In a 2009 speech, Assistant Attorney General Lanny Breuer stated that,
“[i]n some foreign countries and under certain circumstances, nearly every aspect of the approval, manufacture, import, export, pricing, sale and marketing of
a drug product may involve a ‘foreign official’” as defined in the FCPA.71
In Africa, sponsors of clinical trials, CROs and American lead investigators
conducting a clinical trial may confront a number of scenarios that could give
rise to FCPA liability as a result of having conferred “any money . . . [or] anything of value” to a foreign official in order to influence official acts or obtain
business.72 While making an impermissible direct payment to a government official to approve an increased study enrollment, for example, would clearly violate the statute, possible liability may attach to many other activities surrounding
a trial that are not so unambiguously prohibited. In many countries, hospitals
hosting clinical trials are most often government-owned or government-controlled, and physicians and other staff administering a clinical trial are government or parastatal employees.73 As government or parastatal employees, these
medical professionals are regarded as “foreign officials” under the FCPA.74
Payments to government officials (including physician-investigators) who
are administering or conducting a trial do not become an impermissible payment
made “to influence official acts or obtain business” if the payments are used to
fund the trial and are calibrated to fair market value for the services performed.75
However, the payments must not be intended to gain local regulatory approval
to conduct the trial or to influence the exercise of any government official’s true
discretionary authority.76 Monetary payments are not the only transfers to foreign government employees that may implicate the FCPA. Authorship on papers, for example, when undeserved under applicable academic criteria, may be
a thing “of value” under the FCPA, because authorship conveys professional
70. See Gardiner Harris & Natasha Singer, U.S. Inquiry of Drug Makers is Widened, N.Y. TIMES,
Aug. 13, 2010, http://www.nytimes.com/2010/08/14/health/policy/14drug.html?_r=1.
71. Id. (further noting that the depth of involvement of foreign governments and officials in foreign
health systems, and the competitive nature of the industry, creates risk for illegal payments that could
corrupt the process of drug development, manufacture, import, export, and pricing).
72. 15 U.S.C. § 78dd-1(a)(3) (2010).
73. See B. Hanifin, M. Barnes, & N. Berg, Corruption Risks in International Clinical Trials: Navigating Between Anti-Bribery Laws and Local Circumstances, BLOOMBERG BNA MEDICAL RES. L. &
POL’Y REPORT 1 (Jan. 6, 2016), https://www.ropesgray.com/newsroom/news/2016/01/In-BloombergBNA-Medical-Research-Law-Policy-Report-Litigators-Review-Corruption-Risks.aspx.
74. See 15 U.S.C. § 78dd-1(f)(1)(a) (2010) (defining “foreign official” as “any officer or employee
of a foreign government or any department, agency, or instrumentality thereof, or of a public international
organization, or any person acting in an official capacity for or on behalf of any such government or
department, agency, or instrumentality, or for or on behalf of any such public international organization.”).
75. See generally, 15 U.S.C. § 78dd-1 (2010) (providing an exception for payment(s) to foreign governments and officials for “routine governmental action” The fair market value of payments tends to support that bona fide services were purchased).
76. See id. (providing that any payment to a foreign government official is impermissible if the payment is for purposes of influencing the foreign official in his or her official capacity).
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prestige and career opportunities. Therefore, in the allocation of any benefit,
monetary or otherwise, clinical trial sponsors, CROs and lead investigators
should assure that any benefits or payments are justifiable under FCPA standards.
In addition to the FCPA, multinational entities conducting clinical trials in
Africa must also comply with the United Kingdom Bribery Act if they “carr[y]
on a business, or part of a business, in any part of the United Kingdom.”77 The
scope of the United Kingdom Bribery Act extends to U.S.-based research sponsors that carry out research in Africa if they, for example, are registered to do
business in the United Kingdom or sell pharmaceutical, medical device, or biological products there. Liability is triggered when a person “associated” with the
covered commercial entity “bribes another person intending to obtain or retain
business for [the entity] or to obtain or retain an advantage in the conduct of
business for [the entity]” and the entity lacks “adequate procedures designed to
prevent persons associated with [it] from undertaking such conduct.”78 The Act
broadly defines an associated person to include “a person who performs services
for or on behalf of [the entity],” a standard which is determined “by reference to
all the relevant circumstances and not merely by reference to the nature of the
relationship between [the person] and [the entity].”79 Consequently, all U.S.based and local personnel at a sponsor’s trial site in Africa potentially could be
determined to be “affiliated persons,” and therefore the sponsor must ensure that
its procedures are adequate to prevent all its potential affiliates from engaging in
bribery prohibited under the Act.
7. False Claims Act
The federal False Claims Act (“FCA”) provides that any person who
“knowingly presents, or causes to be presented, a false or fraudulent claim for
payment or approval” will be “liable to the United States Government for a civil
penalty of not less than $5,000 and not more than $10,000 [as adjusted for inflation], plus three times the amount of damages which the Government sustains
because of the act of that person.”80
Academic institutions that receive funding from government agencies, such
as NIH or CDC, to conduct research studies in Africa encounter several situations
that could be characterized as having presented or having caused to be presented
a false or fraudulent claim. For example, institutional grantees can risk FCA
liability if project investigators charge to a grant costs that do not relate to the

77.
78.
79.
80.

Bribery Act 2010, c. 23 § 7 (U.K.).
Id.
Id. at § 8.
31 U.S.C. § 3729 (2012).
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specific objects of the grant, or if required procurement processes are not followed. Additionally, for example, institutional grantees may face liability under
the FCA for excessive time and effort charges on federally funded grants to support personnel salaries.81
8. Registration on ClinicalTrials.gov
The Food and Drug Administration Act of 1997 instructed the NIH to create
a database listing clinical trials of drugs that treat “serious or life-threatening
conditions.”82 In 2000, the NIH released the ClinicalTrials.gov website.83 The
categories of clinical trials required to be registered on ClinicalTrials.gov were
significantly expanded under the Food and Drug Administration Amendments
Act of 2007 (“FDAAA”).84 The FDAAA requires that all clinical trials of drugs,
biologics and devices be registered.85 Additionally, the FDAAA requires that
summary results of registered trials of products approved, licensed or cleared by
the FDA be posted on ClinicalTrials.gov.86 Under the FDAAA, the registration
requirement applies to any trial that is an “applicable clinical trial,” defined as “a
controlled clinical investigation, other than a phase I clinical investigation” of a
drug subject to NDA registration or a biologics license application.87 Therefore,
clinical trials conducted abroad must also be registered and listed on ClinicalTrials.gov if they are conducted as phase II or III trials in support of an NDA.
In a new rulemaking, NIH clarified that some entirely ex-U.S. clinical trials
are not subject to registration. NIH issued a Notice of Proposed Rulemaking
interpreting the provisions of the FDAAA on November 19, 2014 and issued a
Final Rule on September 21, 2016.88 The Final Rule implements the FDAAA’s
mandated expanded registry and results bank and also clarifies, in the preamble,
that a clinical investigation of a drug, device or biological product that is being
conducted entirely outside of the U.S. (i.e., a trial without any sites in the U.S.
or in any territory of the U.S.) may or may not be an “applicable drug clinical

81. See, e.g., Yale University to Pay $7.6 Million to Resolve False Claims Act and Common Law
Allegations, U.S. DEP’T OF JUSTICE (Dec. 23, 2008), https://oig.nasa.gov/press/pr2009-B.pdf.
82. Food and Drug Administration Modernization Act of 1997, Pub. L. No. 105-115, § 113, 111 Stat.
2295, 2311 (1997).
83. See U.S. NAT’L INST. OF HEALTH, History, Policies, and Laws, CLINICALTRIALS.GOV,
https://clinicaltrials.gov/ct2/about-site/history (last updated July 2017) (providing a timeline of information relating to the expansion of the ClinicalTrials.gov website).
84. See Food and Drug Administration Amendments Act of 2007 (FDAAA), Pub. L. No. 110-85,
121 Stat. 904 (2007) (codified at 42 U.S.C. 282).
85. See id.
86. See id.
87. Id.
88. See Clinical Trials Registration and Results Submission, 79 Fed. Reg. 69,466 (Nov. 19, 2014);
see also Clinical Trials Registration and Results Submission, 81 Fed. Reg. 64,982 (Sept. 21, 2016).
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trial” (defined to include biologics) or an “applicable device clinical trial” required to be reported on ClinicalTrials.gov.89 Whether an exclusively ex-U.S.
trial is an “applicable drug clinical trial” under the Final Rule is determined by
whether the drug is subject to an NDA or to a biologics license application.90 If
the drug or biological product is “manufactured outside of the United States or
its territories, the clinical investigation sites are all outside of the United States,
and the clinical investigation is not being conducted under an IND, [then] the
drug or biological product would not be considered to be subject” to an NDA or
to biologics license application, thus the clinical investigation would not be an
“applicable drug clinical trial” requiring registration on ClinicalTrials.gov.91
Likewise, if a clinical investigation for a device product is not conducted under
an IDE and “is manufactured outside of the United States or its territories, and
the clinical study sites are all outside of the United States and/or its territories”
then the trial is not an applicable device clinical trial and is not subject to registration on ClinicalTrials.gov.92 The Final Rule clarifies for sponsors conducting
exclusively ex-U.S. clinical trials for drugs not to be marketed within the U.S.
that the related clinical trials are not required to be registered with the FDA.
Biomedical journals provide another significant professional impetus for
both academics and industry sponsors to register clinical trials on ClinicalTrials.gov. The International Committee of Medical Journal Editors (“ICMJE”) requires all journals seeking its approval to enforce the ICMJE policy requiring
“registration of clinical trials in a public trials registry at or before the time of
first patient enrollment as a condition of consideration for publication.”93 ICMJE
specifically deems ClinicalTrials.gov to be an acceptable public trials registry,
among others.94
III. ETHICAL GUIDELINES FOR CLINICAL RESEARCH AND POTENTIAL ETHICAL
ISSUES AFFECTING CLINICAL TRIALS IN AFRICA
In countries where human subjects research law is meager, non-existent or
weakly enforced, a series of ethical guidelines nevertheless provide standards for
research involving human subjects. Subsection A provides a brief overview of
the history of the ethical principles applicable to clinical research in foreign
countries. Subsection B applies one set of ethical principles, the International
Ethical Guidelines for Health-Related Research Involving Humans to certain

89. 81 Fed. Reg. 64,982, 65,013, 65,015.
90. See id. at 65,015.
91. Id.
92. Id.
93. Clinical Trial Registration, INT’L COMM. OF MED. J. EDITORS, Jan. 29, 2016, http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html.
94. See id.
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ethical challenges likely to arise when clinical trials are conducted by sponsors
and investigators in Africa.
A. Sources of Ethical Principles
After World War II, the Nuremberg Code (“the Code”) was drafted in response to the medical experiments that Nazi doctors carried out on concentration
camp prisoners.95 The Code lays out principles of ethical experimentation on
human subjects.96 Officially, the Code was never adopted by the international
community and, subsequently, questions emerged regarding “the applicability of
its more stringent provisions when the research [was] clearly for the benefit of
the patient.”97 Subsequent ethical guidelines have emerged to clarify and expand
upon the Code.98
One subsequent ethical guideline, the Declaration of Helsinki (the “Declaration”), was promulgated by the World Medical Association in 1964 and is addressed primarily to physicians, although the Association encourages others involved in medical research involving human subjects to adopt the Declaration’s
principles.99 When a physician is involved in human subjects research, the Declaration provides that it is “the duty of the physician to promote and safeguard
the health, well-being and rights of patients, including those who are involved in
medical research.”100
In 1982, the Council for International Organizations of Medical Sciences
(“CIOMS”) released the first version of its International Ethical Guidelines for
Health-Related Research Involving Humans (the “Guidelines”).101 Most recently updated in 2016, these Guidelines aim to “provide internationally vetted
ethical principles and detailed commentary on how universal ethical principles
should be applied, with particular attention to conducting research in low-resource settings.”102 The Guidelines provide that, “[t]o ensure that people in low95. See Dawn Joyce Miller, Comment, Research and Accountability: The Need for Uniform Regulation of International Pharmaceutical Drug Testing, 13 PACE INT’L L. REV. 198, 198–99 (2001) (stating
that “the Nuremberg trials resulted in the first enunciation of ethical principles for medical research involving human beings—the Nuremberg Code”).
96. See generally The Nuremburg Code, OFF. OF HIST. NAT’L INSTIT. OF HEALTH, https://history.nih.gov/research/downloads/nuremberg.pdf (last visited Sept. 18, 2017) (setting forth several principles including voluntary consent of human subjects and avoidance of unnecessary physical or mental suffering).
97. Miller, supra note 1, at 203.
98. See id. at 203 n.38, 205 (noting that the Declaration of Helsinki has expanded upon the Nuremburg Code’s protections).
99. See WORLD MED. ASS’N, supra note 48 at 199.
100. Id.
101. See Int’l Ethical Guidelines for Health-Related Research Involving Humans, COUNCIL FOR INT’L
ORG. MED. SCI., https://cioms.ch/wp-content/uploads/2017/01/WEB-CIOMS-EthicalGuidelines.pdf (last
modified 2016).
102. Id. at viii.
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resource settings receive equitable benefit from their participation in health-related research . . . local social value [must] be created.”103 Additionally, the
Guidelines require that research in low-resource settings involve cooperation
with government and other stakeholders “to make available as soon as possible
any intervention or product developed, and knowledge generated . . . and to assist in building local research capacity,” including for example “training laboratory personnel” and “educating the public about the nature of research and the
benefits resulting from a particular study.”104
The pharmaceutical trade organization PhRMA has published its Principles
on Conduct of Clinical Trials, which is voluntary for its members to adopt.105
These principles require IRB review, the informed consent of human research
study participants, and mandate that sponsors of trials in the developing world
seek to collaborate with relevant parties, such as local health authorities and host
governments, in order “to address issues associated with the conduct of the proposed study and its follow-up.”106
B. Ethical Issues Affecting Clinical Trials in Africa
The emergence of ethical guidelines for human subjects research in the
post-World War II era indicates the perennial nature of difficult ethical questions
that inevitably arise in working with human research subjects. When research
subjects are located in the developing world or emerging economies, applying
the ethical guidelines often poses unique challenges. This section applies the
International Ethical Guidelines for Health-Related Research Involving Humans
to some difficult paradigms that may emerge in conducting clinical trials in Africa.
1. Obtaining Adequate Informed Consent
Assuring adequate informed consent poses serious challenges for sponsors
and investigators in many African countries. Investigators seeking informed
consent may need to navigate barriers including language, comprehension, and
local cultural norms.107 In some areas, “the use of local languages may facilitate
the communication of information to potential participants” and allow the investigator to ensure the potential subjects’ comprehension.108 Investigators working
in such circumstances must take into account the competence and neutrality of
103. Id. at 3.
104. Id. at 3, 5.
105. See PRINCIPLES ON CONDUCT OF CLINICAL TRIALS: COMMUNICATION OF CLINICAL TRIAL
RESULTS, PHRMA 2 (rev. ed. 2014), http://phrma.org/sites/default/files/pdf/042009_clinical_trial_principles_final_0.pdf.
106. Id. at 11.
107. See COUNCIL FOR INT’L ORG. MED. SCI., supra note 101, at 26, 34.
108. Id. at 35.
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local translators to ensure that intended messages are being appropriately conveyed to research subjects.
Additionally, investigators in the developing world may face challenges in
ensuring that the prospective subject has adequately understood the information
provided. In countries with a low level of education among research subjects,
investigators may have difficulty determining whether a person has understood
the plan of research sufficient to give informed consent.109 Commentary in the
Guidelines recommends that the investigator should give each potential research
subject the “opportunity to ask questions” and provide the potential subject answers before or during the research.110 Researchers also should use “evidencebased methods for imparting information to ensure comprehension.”111
Finally, investigators must respect the customs of a community while simultaneously ensuring that adequate individual consent is obtained. For example,
in some communities, the permission of a community leader, council of elders,
or other designated authority may be expected before investigators approach individuals as potential human subjects.112 For example, it has been reported that
the African Malaria Network Trust has obtained the permission of community
leaders to conduct trials in the village of Balonghin, Burkina Faso; two sites in
Mali; a site in Gabon; and various communities in the town of Bagamoyo, Tanzania.113 However, the Guidelines note that individual consent must still be obtained, and a community leader’s consent cannot be used as a substitute.114
The potential difficulties in obtaining adequate informed consent in certain
circumstances are highlighted by the Pfizer clinical trial of Trovan in Nigeria.115
In 1996, northern Nigeria experienced an epidemic of bacterial meningitis.116
During the outbreak, Pfizer sponsored a study of an experimental anti-meningitis
drug, Trovan, on a group of 200 pediatric subjects.117 Eleven children died in
the trial, five of whom had taken Trovan and six of whom had taken another
older antibiotic used for comparison.118 The study proved contentious on multiple grounds, with a central issue being whether informed consent had been

109. See Meier, supra note 1, at 540.
110. COUNCIL FOR INT’L ORG. MED. SCI., supra note 101, at 34.
111. Id.
112. See id. at 35.
113. See Aceme Nyika et al., Engaging Diverse Communities Participating in Clinical Trials: Case
Examples from Across Africa, 9 MALARIA J. 1–11 (2010).
114. See COUNCIL FOR INT’L ORG. MED. SCI., supra note 101, at 35.
115. See Donald G. McNeil, Jr., Nigerians Receive First Payments for Children Who Died in 1996
Meningitis
Trial,
N.Y.
TIMES
(Aug.
11,
2011),
available
at
http://www.nytimes.com/2011/08/12/world/africa/12nigeria.html.
116. See id.
117. See id.
118. See id.
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properly obtained from the children or their guardians.119 Plaintiffs in subsequent litigation alleged that the study had not appropriately implemented the
treatment protocol requiring “researchers to offer or read the subjects documents
requesting and facilitating their informed consent,” which researchers allegedly
did not do “in either English or the subjects’ native language of Hausa.”120
The Trovan clinical trial provides at least two lessons for investigators who
seek to obtain informed consent when working in Africa. First, ensuring that
local subjects are sufficiently informed so as to be able to give adequate consent
is likely to require coordination with local parties who can explain the potential
risks and rewards of trial participation in linguistically appropriate and culturally
competent language.121 Although this was apparently done in the Trovan study,
records of the informed consent process were generally lacking.122 Second,
therefore, it is best to create a record of the informed consent of research subjects
or their guardians, if only to avoid future disputes and litigation. When working
with populations with high rates of illiteracy, written consent may be difficult to
obtain, and alternative methods of documentation, such as audio or video recordings of statements of consent may be desirable, although investigators should
also work with local partners to determine whether these technologies are likely
to have a deterrent or coercive effect on potential subjects’ participation.123
The HIVNET 012 Perinatal HIV Prevention Study, carried out in 1997 in
Uganda, also illuminates the difficulties investigators face in obtaining adequate
informed consent.124 At the time of the study, “the standard of care for preventing mother-to-child transmission in both the United States and Europe” consisted
of a three-part maternal-infant zidovudine regimen.125 Due to a variety of factors, including “poor public health, clinical, and laboratory infrastructure and capacity [and] high rates of out-of-hospital delivery” the three-course regimen was

119. See Abdullahi v. Pfizer, Inc., 562 F.3d 163, 169–70 (2d. Cir. 2009).
120. Id.
121. See, e.g., Donald J. Krogstad, et al., Informed Consent in International Research: The Rationale
for Different Approaches, 83 AM. J. TROPICAL MED. & HYGIENE 743, 746 (2010) (recommending that
community leaders participate in the consent process, where appropriate, to ensure participants understand
the risks and benefits).
122. See Joe Stephens, Panel Faults Pfizer in ‘96 Clinical Trial In Nigeria, WASH. POST, May 7, 2006,
available
at
http://www.washingtonpost.com/wp-dyn/content/article/2006/05/06/AR2006050601338.html.
123. See Maria Kuthning & Ferdinand Hundt, Aspects of Vulnerable Patients and Informed Consent
in Clinical Trials, 11 GER. MED. SCI. 1, 9 (2013); see also Niranjan G. Kulkarni, Audio-Video Recording
of Informed Consent Process: Boon or Bane, 5 PERSP. CLINICAL RES. 6 (2014).
124. See INST. OF MED. OF THE NAT’L ACADEMIES, REVIEW OF HIVNET 012 PERINATAL HIV
PREVENTION STUDY 27 (2005).
125. Id.
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impractical in Uganda.126 The HIVNET 012 Study therefore tested a less intensive regimen, consisting of a shorter course of antiretroviral drugs, for its efficacy
in preventing mother-to-child HIV transmission.127
In a report affirming the validity of the study’s questioned findings, the Institute of Medicine (“IOM”) identified numerous ethical issues that the investigators had faced in obtaining adequate informed consent.128 The report broadly
noted that investigators “must tailor both the information and the way they convey it to the needs of participants,” including “forms of documentation that are
sensitive to local concerns,” noting in particular that “in some settings, [there
may be] a fear of signing documents.”129 These cultural differences challenge
investigators to adapt standard informed consent practices to local circumstances.
One issue that the HIVNET 012 investigators confronted was whether a
father’s informed consent should be obtained.130 The study’s consent forms included a line for the father of the fetus or infant to sign if he was available.131
The investigators counseled study participants to involve fathers in the decisionmaking, but when participants “refused or were unable to involve fathers . . . the
research team deemed those fathers ‘unavailable.’”132 In its review of the study,
the IOM found that obtaining informed consent from fathers was not required by
U.S. federal regulations, which only require a father’s consent when the research
is solely of possible benefit and risk to the fetus, without any benefit or risk to
the mother.133 In the HIVNET 012 study, however, both maternal and fetal
health were involved, so the fathers’ consent was not required.134 Moreover, the
IOM report noted that requiring the father to be involved in the study posed “concerns about violating confidentiality by revealing the women’s HIV status to the
fathers, especially given the stigmatization of HIV-positive individuals.”135 This
study therefore provides an example of the moral and legal risks involved in implementing an interventional drug study in a low-resource setting.
2. Informed Consent Implications in Project Wind-Up and Wind-Down
U.S. and E.U.-based staff can, without realizing, raise expectations for continued support, involvement or resources. Cultural differences may give rise to
126. Id. at 28.
127. See id. at 28–29.
128. See id. at 89.
129. Id.
130. See id. at 90.
131. See id.
132. Id.
133. See id. at 90–91.
134. INST. OF MED. OF THE NAT’L ACADEMIES, supra note 124, at 91(noting that some medical benefits arguably did accrue to the pregnant women).
135. Id. at 90.
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miscommunicated expectations such that research subjects may not realize that
the foreign investigator and his or her foreign institution have not entered into a
treatment relationship with them and that their actual relationship is different in
character and duration from a treatment relationship.136 To satisfy the duty to
obtain informed consent, investigators working in circumstances where the nature of the research may be unclear have an ethical duty to ensure that they communicate to research subjects “how the research differs from routine medical
care.”137 Critically, for subjects who are unfamiliar with controlled trials, obtaining adequate informed consent requires “an explanation of features of the
research design, e.g. randomization [and] double blinding. . . .”138
3. Avoiding Undue Inducement When Subjects Lack Medical Alternatives
The comparative ease of recruiting study participants in African countries
may, in some circumstances, raise concerns that a lack of medical treatment alternatives creates an undue pressure on research subjects to participate in a clinical trial.139 In particular, some have noted the possibility that, “[i]n the absence
of health care, virtually any offer of medical assistance (even in the guise of research) will be accepted as ‘better than nothing’ . . .”140 For example, in Africa,
participation in clinical trials was highly valued in the past because it was, for
many, the only means of accessing treatment for HIV/AIDS.141
In clinical trials, health care that is essential to the safe conduct of the research, as well as medical services unrelated to the study, may be provided to
research subjects. The Guidelines state that “[w]hen participants’ health needs
during and after research cannot be met by the local health infrastructure or the
participant’s pre-existing health insurance, the researcher and sponsor must make
prior arrangements for adequate care for participants with local health authori-

136. See Nicholas A. Christakis, The Ethical Design of an AIDS Vaccine Trial in Africa, 18 HASTINGS
CTR. REPORT 31, 35 (1988) (noting that “subjects with relatively little understanding of medical aspects
of research participation . . . [may be] under the mistaken notion that they are being treated. . . .”).
137. COUNCIL FOR INT’L ORG. MED. SCI., supra note 101, at 103.
138. Id. at 105.
139. See Esther Chang, Note, Fitting A Square Peg into a Round Hole?: Imposing Informed Consent
and Post-Trial Obligations on United States Sponsored Clinical Trials in Developing Countries, 11 S.
CAL. INTERDISC. L. J. 339, 342, 353 (2002) (recognizing the relative ease in recruiting participants in
African countries for certain studies and that participants with little access to care for life-threatening
illnesses may face undue influence to enroll in a trial); see also Paul S. Appelbaum et al., Voluntariness
of Consent to Research: A Conceptual Model, 39 HASTINGS CTR. REPORT 30, 30-31 (2009) (recognizing
that issues of impaired voluntariness can arise where patients who otherwise lack access to medical care
are invited to participate in clinical trials).
140. Meier, supra note 1, at 537 (citing George J. Annas & Michael A. Grodin, Research Forum:
Ethics and Studies of HIV, Human Rights and Maternal-Fetal HIV Transmission Prevention Trials in
Africa, 88 AM. J. PUB. HEALTH 560, 562 (1998)).
141. See NWABUEZE, supra note 2 at 2 (2013).
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ties, members of the communities from which persons are drawn, or nongovernmental organizations such as health advocacy groups.”142 Additionally, the
Guidelines note that addressing participants’ health needs requires researchers
and sponsors to “make plans for . . . how care will be provided during the research when researchers discover conditions other than those under study.”143
For clinical trials conducted in resource-poor settings in Africa, investigators must be aware of how the availability of health care services may affect the
choices of research subjects.144 The Guidelines note that providing medical services as a component of a clinical trial has the potential to run afoul of an ethical
duty to avoid compensation so large that it creates an undue pressure to consent
against the subject’s better judgment.145 However, the Guidelines do not prohibit
all research when there is merely a possibility that subjects will be induced to
participate in a trial because it offers benefits relative to the routinely available
medical care.146 Noting that “the compensation that makes some people volunteer against their better judgment depends on their personal situation,” the Guidelines provide that “[r]esearch ethics committees must evaluate monetary and
other forms of compensation in light of the traditions and socio-economic context of the particular culture and population in order to determine whether the
average participant expected to enrol[l] in the study is likely to participate in the
research against his or her better judgment because of the compensation offered.”147 Therefore, in order to provide ethically sound financial and medical
benefits to clinical trial participants in resource-poor settings in Africa, sponsors
and investigators must take into account the potential for undue inducement,
when the participants’ access to alternative sources of medical care is limited.
4. Ethical Issues in Identifying Human Subjects
When working in African countries, certain ethical challenges emerge related to the identification of research subjects. One set of challenges relates to
the equity of the decision to locate such research in the country with populations
and communities with limited resources.148 An additional set of challenges

142. COUNCIL FOR INT’L ORG. MED. SCI., supra note 101, at 21.
143. Id.
144. See Ezekiel J. Emanuel et al., What Makes Clinical Research in Developing Countries Ethical?
The Benchmarks of Ethical Research, 189 J. INFECTIOUS DISEASES 930, 930 (2004) (“[While] limited
health-care services . . . neither cause nor are necessary for exploitation, they increase the possibility of
such exploitation.”).
145. See COUNCIL FOR INT’L ORG. MED. SCI., supra note 101, at 53 (“Compensation [broadly defined
to include non-monetary forms such as free health services] must not be so large as to induce potential
participants to consent to participate in the research against their better judgment (‘undue inducement’).”).
146. See id. at 53–54.
147. Id. at 54.
148. See id. at 2–5.
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emerges when selecting research subjects from among the population of the developing country.
When working in populations with limited resources, the Guidelines require
that the sponsor and investigator must make every effort to ensure that “the research is responsive to the health needs or priorities” of the population or community and that “any intervention or product developed, and knowledge generated” will be made available “for the population or community in which the
research is carried out.”149 First, responsiveness requires more than a determination that a studied disease is prevalent in the population, and includes further
analysis into whether successful interventions are to be made available to the
population, especially if the population may be unable to afford even a new drug
that is cheaper than the standard treatment in other countries.150 Second, “[p]osttrial access plans are of particular concern” as a means of ensuring availability
of products developed in “low-resource settings where governments lack the
means or infrastructure to make such products widely available.”151 However,
the Guidelines also provide that issues of post-trial availability in populations
and communities should not be construed to preclude studies evaluating novel
concepts, for example, in cases seeking to evaluate the efficacy of an experimental drug in treating a disease that occurs only in low-resource settings and
“such research could not be carried out reasonably well in more developed communities.”152 In such instances, although there would not be a specific product
that could be made available to the population or community at the end of the
experimental trial even if the concept is found to be valid, the research may be
ethically justifiable as “subsequent phases of research could result in a product
that would be made reasonably available.”153
Once a sponsor or sponsor-investigator determines that a clinical trial site
will be located within a particular country, another set of ethical considerations
apply to the selection of individual research subjects from among the population.154 Ethical guidelines mandate that “[g]roups that are unlikely to benefit
from any knowledge gained from the research should not bear a disproportionate
share of the risks and burdens of research participation” and “[g]roups that are
under-represented in medical research should be provided appropriate access to
participate.”155 Interpreting this provision, the Guidelines’ commentary provides
that, “[w]hen burdens or benefits of research are to be apportioned unequally

149. Id. at 3.
150. See COUNCIL FOR INT’L ORG. OF MED. SCI., supra note 101, at 2–5.
151. Id. at 4–5.
152. Id. at 5.
153. Id. at 5.
154. See id. 7 (stating that “no group or class of persons [should] bear more than its fair share of the
risks or burdens from research participation.”).
155. See COUNCIL FOR INT’L ORG. MED. SCI., supra note 101, at 7.
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among individuals or groups, the criteria for unequal distribution should be scientifically and ethically justified rather than arbitrarily or conveniently chosen.”156 To satisfy these ethical obligations, sponsors and investigators should
be cognizant in their selection of particular ethnic or social groups within the
country for possible study recruitment. Additionally, if there will be waiting lists
for clinical trial enrollment, it is essential that any prioritization status to certain
subjects be ethically justifiable. For example, a sound scientific reason may justify prioritizing subjects with particularly acute conditions, if relevant to the research being conducted. However, other potential criteria for participation, such
as family relation to local clinical staff, should be avoided as not scientifically
justifiable.
IV. CONCLUSION
Clinical trials conducted in Africa offer numerous potential benefits for
studying diseases impacting public health, for pharmaceutical companies seeking to test the efficacy of new drugs, for local investigators seeking academic
opportunities, and for local populations that may have lacked historical access to
clinical trials or even to basic medical care. Conducting clinical trials in Africa,
however, poses unique legal considerations that emerge from the complex framework of foreign and U.S. laws that may apply to foreign clinical trial sites. Additionally, clinical trials in Africa can present a number of ethically challenging
situations with which sponsors and investigators may be unfamiliar. In navigating challenges such as obtaining informed consent in unfamiliar cultural and
linguistic conditions, sponsors and investigators will find that the most essential
ingredient to a successful research or service project in a developing country is
having a competent and trustworthy local partner institution or set of investigators. Identifying such entities and persons contributes significantly to ethical and
scientifically rigorous research in such projects.
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